NASDAQ: KLRAKailera Therapeutics Inc Stock
$24.61-1.39 (-5.35%)
Updated Apr 20, 2026
KLRA Price
$24.61
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$23.69
52 Week High
$28.23
P/E
-0.03x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$148.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.16
Operating Cash Flow
-$120M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KLRA Overview
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KLRA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KLRA
Ranked#160 of 465
Ranked#160 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.92 | A | |
| $202.56 | A | |
| $9.19 | A |
Be the first to know about important KLRA news, forecast changes, insider trades & much more!
KLRA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KLRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KLRA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KLRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KLRA due diligence checks available for Premium users.
Valuation
KLRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
17.94x
Market
31.11x
KLRA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
KLRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$692.3M
Liabilities
$56.4M
Debt to equity
-0.16
KLRA's short-term assets ($557.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLRA's short-term assets ($557.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KLRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
KLRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Kailera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.